



Dr. Saul Martinez Montero is the Executive Director and Head of Oligonucleotide Therapeutics at Dyne Therapeutics, where he leads discovery efforts focused on developing novel oligonucleotide payloads for the treatment of neuromuscular diseases. He previously held scientific and strategic leadership roles at Basecure Therapeutics, Aligos Therapeutics, and Johnson & Johnson. A recognized expert in RNA therapeutics, Dr. Martinez Montero has led the discovery of two siRNAs that are currently in clinical development. He earned his Ph.D. in organic chemistry from the University of Oviedo in Spain and completed postdoctoral training at McGill University in Montreal, Canada. Dr. Martinez Montero is the author of 22 publications in leading scientific journals and an inventor on more than 20 issued and pending patents.